Probability of Developing Non-Hodgkin Lymphoma
1 in 48 (2.1%)
Lifetime probability in US
Approximately 2.1% of Americans will develop non-Hodgkin lymphoma in their lifetime, making it the seventh most common cancer.
Non-Hodgkin lymphoma (NHL) encompasses over 60 different subtypes of lymphatic system cancer, with a combined lifetime risk of about 2.1% in the United States. It is more common in men than women and incidence increases with age, with the median diagnosis at age 67.
Risk factors include immunodeficiency conditions (HIV/AIDS, organ transplant recipients on immunosuppressive drugs), autoimmune diseases (rheumatoid arthritis, Sjogren syndrome, celiac disease), chronic infections (H. pylori, hepatitis C, Epstein-Barr virus), and exposure to certain pesticides and herbicides.
The 5-year survival rate for NHL varies dramatically by subtype, from over 90% for some indolent forms to under 30% for aggressive subtypes. Overall, the 5-year survival rate is approximately 74%. Treatment depends on subtype and stage, ranging from watchful waiting for indolent lymphomas to aggressive chemotherapy, immunotherapy (rituximab), radiation, and CAR T-cell therapy for aggressive forms.
Use This in a Decision
Plug this probability into our expected value calculator to make a data-driven decision.
Start a Decision